Avène Retrinal Multi-Corrective Cream review: the improved preparation and its study footnotes

The official indexed product record identifies Retrinal 0.1% Intensive Multi-Corrective Cream as P0008259, states 1.0 fl oz and displays $68. It says the item was formerly Retrinal 0.1 Intensive Cream and has an improved formula and updated packaging. That explicit manufacturer wording supports a version distinction rather than an assumption that only the name changed.

The official page version reviewed came from a public index. The exact time it was saved is unknown, so its stock display cannot guarantee present availability. The vehicle-and-strength guide separates preparation identity, active concentration and quantity. Here, those advertised fields are present, while the actual label and contents of an individual container remain unexamined.

The public ingredient declaration starts with Avène thermal spring water, caprylic/capric triglyceride, glycerin and squalane. It also includes shea butter, safflower seed oil, niacinamide, retinal, sodium hyaluronate and other components. Those entries belong to the improved cream's record, rather than a recipe reconstructed from the most familiar active. Complete ingredient declaration

The list can make a component question precise, but it does not reveal every concentration or assess an individual's response. Our combination-ingredient guide considers that difference. A full website declaration is evidence about a published preparation version; it is not authentication of a purchased item or proof that the whole base produces the advertised comfort for every reader.

Avène advertises 0.1% retinaldehyde, while the declaration lists RETINAL. The manufacturer's name and list therefore provide connected active-identification information for this specific improved preparation. They do not establish an equivalent tretinoin percentage or a reason to choose a higher-numbered retail or prescription item. Active and formula record

The INKEY Starter Serum review separately follows named retinoid and complex percentages within another preparation. Comparing the evidence questions is useful without transferring either formula's results. AAD distinguishes retinol from prescribed tretinoin within the wider retinoid family. That general framework is not a trial of Avène's cream, a personal strength decision or proof that two compounds have the same clinical effect.

The page reports that 89% saw improved texture, 92% improved firmness and 87% improved smoothness. Its footnote identifies a 57-day study based on 44 women aged 45–65. These details belong together, with the endpoints retained as the manufacturer describes them. Clinical summary and footnotes

The wording does not resolve whether each outcome was instrument-measured, investigator-rated or self-assessed, and the complete underlying report was not obtained. The age group also should not disappear into a universal promise. The FTC evidence guidance explains why participant groups, duration and outcome methods matter. The summary supplies some useful parameters while leaving others open; it does not predict one person's response to the improved cream.

Avène's three-times retinaldehyde wording cites a 1994 paper about topical retinaldehyde on human skin. Its ten-times-faster statement cites a 1990 paper about retinol and retinal metabolism in cultured human keratinocytes. Those reference descriptions concern different research subjects and are not the same as the 44-woman account beside the cream's appearance percentages. Referenced research

We read the manufacturer's citations and surrounding claims, not the complete underlying papers. A cell-metabolism reference cannot alone establish ten-times-better wrinkle results for this finished preparation. The FTC guidance distinguishes ingredient evidence from the complete product claim it might imply. Our RoC night-cream review separately examines another brand's ingredient comparison, without joining their slogans into a clinical ranking.

The indexed official record connects $68 and 1.0 fl oz to the improved P0008259 cream. That helps identify the offer considered here. It does not confirm a current final charge, a completed purchase or the exact packaging and ingredient version that would arrive. No sample or delivered container was examined. Offer details

The options comparison keeps those commercial fields separate from prescription and pharmacy records. A quantity does not establish how long a preparation should be used, its individual instructions or its stability under uncertain conditions. The manufacturer's packaging-update statement makes exact item identity more relevant, but it cannot provide this review with the missing history of an unexamined container.

The ingredient list includes Red 33 alongside the cream's other components. When discussing cosmetic oversight, FDA says cosmetics and ingredients are generally not preapproved, with an important exception for some color additives. That exception should remain visible; the framework is not a finding that this particular formula or label has been independently inspected for compliance.

The strongest preparation information is the improved item identity and its full public list. Its clinical summary, ingredient references and free-from claims answer different questions. Manufacturer declaration A professional discussion can use those specifics while retaining the unknown supplied record and individual response. This review offers no procedure timing, handling instructions, compatibility assessment or prescription substitution based on the cream's appearance claims.